Study of the Therapeutic Vaccine (ISA101/ISA101b) to Treat Advanced or Recurrent Cervical Cancer
Status:
Completed
Trial end date:
2018-08-01
Target enrollment:
Participant gender:
Summary
The purpose of the study is to assess the safety, tolerability and the HPV-specific immune
responses of different doses of ISA101 vaccine with or without pegylated IFNα as combination
therapy with carboplatin and paclitaxel.
To qualitatively assess the safety profile and the HPV-specific immune responses of ISA101b
vaccine compared to ISA101 at the same dose levels.
To assess the safety and the HPV-specific immune responses of ISA101b vaccine with
carboplatin, paclitaxel with or without bevacizumab.